2025-04-03 - Analysis Report
## Johnson & Johnson (JNJ) Stock Performance Review

**0. Overview:**

Johnson & Johnson is a multinational medical device, pharmaceutical, and consumer packaged goods company.

**1. Performance Comparison with S&P 500 (VOO):**

JNJ's cumulative return of 30.38% significantly lags behind the S&P 500's return of 89.44% over the analyzed period.  The difference is -59.1%, placing it in the 24.7th percentile of its historical range of performance relative to the S&P 500 (-84.5% to 18.2%). This indicates underperformance compared to the broader market.

**Alpha and Beta Analysis:**

The provided data shows inconsistent alpha and beta values over the years.  While beta consistently hovers around 1, indicating similar volatility to the market, alpha is mostly negative, implying underperformance relative to the market's risk-adjusted return. The exceptions are in 2017-2019, 2018-2020, and 2019-2021 where a positive alpha is observed. However, the recent years display negative CAGR, reflecting a period of underperformance. The market capitalization remains consistently large.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 24.0% | 5.5% | 6.0% | -0.2 | 278.2 |
| 2016-2018  | 9.0% | 12.2% | 2.0% | -0.5 | 263.9 |
| 2017-2019  | 18.0% | 12.2% | -1.0% | 0.2 | 306.7 |
| 2018-2020  | 15.0% | 12.2% | -19.0% | 0.2 | 339.9 |
| 2019-2021  | 29.0% | 9.1% | -44.0% | 0.2 | 378.8 |
| 2020-2022  | 16.0% | 49.1% | 5.0% | 0.2 | 401.4 |
| 2021-2023  | -12.0% | 49.1% | -30.0% | 0.4 | 367.0 |
| 2022-2024  | -26.0% | 49.1% | -48.0% | 0.3 | 349.3 |
| 2023-2025  | -3.0% | 49.4% | -43.0% | 0.3 | 373.1 |


**2. Recent Price Movement:**

* **Closing Price:** $153.25
* **Last Market Price:** $154.84 (a $1.04 increase from the previous close)  This represents a small, positive daily change and does not suggest a significant uptrend or downturn.
* **5-Day Moving Average:** $161.53
* **20-Day Moving Average:** $163.43
* **60-Day Moving Average:** $156.05

The stock price is currently trading below all three moving averages, suggesting a potential downtrend.


**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.4354 (Medium Risk)
* **RSI:** 29.73 (Oversold territory, suggesting potential for a price rebound)
* **PPO:** -0.63 (Negative, indicating bearish momentum)
* **Recent Relative Strength Change:** -0.3 (Short-term downward trend)
* **Expected Return:** -74.9% (This extremely negative expected return relative to the S&P 500 needs further clarification and context.  The methodology behind this calculation should be reviewed).  The implication is that the model projects significant underperformance in the long term (2+ years).

**4. Recent Earnings Analysis:**

The provided EPS and Revenue data shows some fluctuation but generally indicates consistent revenue around $22 Billion.  The massive EPS spike in Q4 2023 needs further investigation as it’s significantly higher than other quarters.  It's crucial to understand if this was a one-off event or a trend.

| 날짜       | EPS     | 매출          |
|------------|---------|---------------|
| 2024-10-23 | 1.12    | 22.47 B$       |
| 2024-07-25 | 1.95    | 22.45 B$       |
| 2024-05-01 | 1.35    | 21.38 B$       |
| 2024-02-16 | 1.68    | 21.39 B$       |
| 2023-10-27 | 10.32   | 21.35 B$       |


**5. Financial Information:**

Revenue remains relatively stable, while profit margins are consistently high (above 68%).  Equity fluctuates slightly quarter to quarter, and ROE is variable. This indicates a generally healthy financial position but with fluctuations in profitability and return on equity.

**Revenue and Profitability:**

| Quarter | Revenue  | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $22.52B | 68.35%       |
| 2024-09-30 | $22.47B | 69.01%       |
| 2024-06-30 | $22.45B | 69.40%       |
| 2024-03-31 | $21.38B | 69.55%       |
| 2023-12-31 | $21.39B | 68.23%       |

**Capital and Profitability:**

| Quarter | Equity   | ROE    |
|---------|----------|--------|
| 2024-12-31 | $71.49B | 4.80%  |
| 2024-09-30 | $70.16B | 3.84%  |
| 2024-06-30 | $71.54B | 6.55%  |
| 2024-03-31 | $70.02B | 4.65%  |
| 2023-12-31 | $68.77B | 5.89%  |


**6. Overall Conclusion:**

JNJ has significantly underperformed the S&P 500 over the analyzed period, exhibiting negative alpha in most years.  While its financials show consistent revenue and high profit margins, recent price action suggests a downtrend.  Technical indicators point to oversold conditions but also bearish momentum.  The extremely negative projected long-term return requires further investigation of the underlying model and assumptions.  A thorough examination of the Q4 2023 EPS surge is needed.  Before making any investment decision, a deeper dive into JNJ's fundamentals, competitive landscape, and future growth prospects is recommended.  The highly negative expected return should be treated with significant skepticism unless the methodology is fully explained and justified.
